EMA’s CHMP has published its meeting highlights from 20–23 April 2026.
Key takeaways from the update
– Five new medicines were recommended for approval.
– Nine medicines were recommended for extensions of their therapeutic indications.
Examples of new medicine recommendations mentioned
– Cenrifki (tolebrutinib): recommended for marketing authorisation for the treatment of non-relapsing secondary progressive multiple sclerosis.
– Itvisma (onasemnogene abeparvovec): recommended for marketing authorisation as a gene therapy for the treatment of spinal muscular atrophy.
The EMA page also lists sections covering CHMP statistics, recommendations for a new biosimilar medicine and a new generic medicine, and notes on withdrawals and other updates.
Read more at https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2026
